BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

  Prader-Willi syndrome is the most common known genetic cause of life-threatening obesity in children.

  December 27, 2017

   · 

  3 min read
• Biotech Beach

  Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency

  Organovo is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs.

  December 27, 2017

   · 

  4 min read
• Policy

  Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit

  Under the terms of the settlement agreement, RGN paid $150,000 to Endonovo Therapeutics and granted an exclusive option to Endonovo to acquire the PEMF assets of RGN for $4.5 million.

  December 27, 2017

   · 

  6 min read
• Biotech Bay

  Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma

  The patents extend exclusivity for the use of MANF and CDNF in the treatment of retinal disorders in Europe into 2031.

  December 27, 2017

   · 

  6 min read
• Business

  Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors

  Arrowhead announced that the board of directors elected veteran biotechnology executive William Waddill as an independent director of the company, with a term beginning effective January 1, 2018.

  December 27, 2017

   · 

  3 min read
• Acasti Pharma Announces Closing of $10M Firm Commitment Offering of Common Shares and Warrants

  The Benchmark Company, LLC and Dawson James Securities, Inc. acted as book-running managers for the offering.

  December 27, 2017

   · 

  6 min read
• Biotech Beach

  Safer Lock Release: City of Citrus Heights Offers Free Safer Locks to Protect Residents From Accidental Poisonings and Addiction

  In a ground-breaking program designed to prevent accidental poisoning and addiction, the City of Citrus Heights, California, will provide 1,000 Safer Lock prescription bottles with locking caps to Citrus Heights parents.

  December 27, 2017

   · 

  3 min read
• Drug Development

  Diffusion Pharmaceuticals Begins Phase III Clinical Trial With TSC in Glioblastoma Multiforme

  The trial will screen 300 patients and enroll 264 in an effort to ensure that results from 236 patients will be available for analysis.

  December 27, 2017

   · 

  10 min read
• Biotech Bay

  Biotricity Closes a Registered Direct Financing and Paves the Way for Bioflux Launch

  The gross proceeds from the offering will be approximately $2.5M before deducting estimated offering expenses.

  December 27, 2017

   · 

  5 min read
• Biotech Bay

  Catalyst Biosciences Announces Closing of Public Offering of Common Stock

  JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. are acting as Joint Book-running Managers and LifeSci Capital LLC is acting as a Co-Manager for the proposed offering.

  December 27, 2017

   · 

  3 min read